11 Stocks That Will Bounce Back According to Analysts

Page 4 of 10

7. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Year-to-Date Performance: -39.75%

Average Price Target Upside Potential According to Analysts: 110.21%

Number of Hedge Fund Holders: 44

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a global biopharmaceutical company that is focused on developing life-changing therapies for some of the most challenging diseases. The company pioneered targeted C3 therapies and now has two approved medicines targeting C3, including the first-ever therapy for geographic atrophy, a leading cause of blindness. According to analysts, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the top stocks that will bounce back.

On April 29, Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and assigned an “Overweight” rating with a price target of $44. The firm noted that the company has faced several recent challenges, specifically with its main drug, Syfovre. The company’s leading drug faced obstacles like an updated safety label, competition from a newly launched rival drug, and issues with an unfunded patient assistance program. Despite these challenges, Cantor Fitzgerald is still optimistic about Syfovre’s future, expecting it to reach peak sales of $1.3 billion, with projections for 2024 already over $600 million. The firm suggested that the second half of 2025 will be pivotal for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), as the company is looking to get approval and launch pegcetacoplan, a C3 inhibitor, for the treatment of C3 Glomerulopathy (C3G). Cantor Fitzgerald believes that if pegcetacoplan is approved and successfully launched, it could introduce a new phase of growth for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS).

Page 4 of 10